Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PYGB | P11216 | 6/20 | 0.36 |
| ▸ | PYGL | P06737 | 3/20 | 0.36 |
| ▸ | PYGM | P11217 | 2/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 4/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8071533 | 1.00 | PYGB (0.36) | PYGBPYGLPYGMMEN1KMT2A | |
| SCHEMBL5551957 | 0.98 | GAA (0.37) | PYGBPYGLPYGMGAA | |
| SCHEMBL9309804 | 0.98 | GAA (0.37) | PYGBPYGLPYGMGAA | |
| SCHEMBL1401860 | 0.98 | GAA (0.37) | PYGBPYGLPYGMGAA | |
| SCHEMBL2381492 | 0.98 | GAA (0.37) | PYGBPYGLPYGMGAA | |
| SCHEMBL25366499 | 0.98 | GAA (0.37) | PYGBPYGLPYGMGAA | |
| SCHEMBL9699515 | 0.98 | GAA (0.37) | PYGBPYGLPYGMGAA | |
| SCHEMBL19326781 | 0.98 | GAA (0.37) | PYGBPYGLPYGMGAA | |
| SCHEMBL22409570 | 0.98 | GAA (0.37) | PYGBPYGLPYGMGAA | |
| SCHEMBL19326770 | 0.98 | GAA (0.37) | PYGBPYGLPYGMGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070184114-A1 | Formulation for topical non-invasive application in vivo | IDEA AG (DE) | 2007-08-09 | — | — | US | claimed |
| EP-1140021-B1 | IMPROVED FORMULATION FOR TOPICAL NON-INVASIVE APPLICATION IN VIVO | IDEA AG (DE) | 2004-08-04 | — | — | EP | claimed |
| EP-1096994-B1 | LIQUID THICKENER FOR SURFACTANT SYSTEMS | UNION CARBIDE CHEM PLASTIC (US) | 2003-10-01 | — | — | EP | claimed |
| JP-2002533379-A | — | — | 2002-10-08 | — | — | JP | claimed |
| US-20020064524-A1 | Formulation for topical non-invasive application in vivo | IDEA AG (DE) | 2002-05-30 | — | — | US | claimed |
| EP-1140021-A1 | IMPROVED FORMULATION FOR TOPICAL NON-INVASIVE APPLICATION IN VIVO | IDEA AG (DE) | 2001-10-10 | — | — | EP | claimed |
| WO-2000038653-A1 | IMPROVED FORMULATION FOR TOPICAL NON-INVASIVE APPLICATION IN VIVO | IDEA AG. (DE) | 2000-07-06 | — | — | WO | claimed |
| US-10751337-B2 | Preservative free ocular compositions and methods for using the same for treating dry eye disease and other eye disorders | Ocugen, Inc. (US) | 2020-08-25 | — | — | US | disclosed |
| EP-3569223-A1 | METHODS AND COMPOSITIONS FOR SUSTAINED DELIVERY OF DRUGS | Intratus, Inc. (US) | 2019-11-20 | — | — | EP | disclosed |
| EP-2493474-B1 | METHODS AND COMPOSITIONS FOR SUSTAINED DELIVERY OF DRUGS | INTRATUS INC (US) | 2019-09-04 | — | — | EP | disclosed |
| US-20180221278-A1 | PRSUSTAINED RELEASE OPTHALMIC FORMUATION AND METHODS FOR USING THE SAME | Ocugen, Inc. (US) | 2018-08-09 | — | — | US | disclosed |
| US-20180153885-A1 | PRESERVATIVE FREE OCULAR COMPOSITIONS AND METHODS FOR USING THE SAME FOR TREATING DRY EYE DISEASE AND OTHER EYE DISORDERS | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2018-06-07 | — | — | US | disclosed |
| US-9877964-B2 | Methods and compositions for treating dry eye disease and other eye disorders | Ocugen, Inc. (US) | 2018-01-30 | — | — | US | disclosed |
| US-20070184114-A1 | Formulation for topical non-invasive application in vivo | IDEA AG (DE) | 2007-08-09 | — | — | US | disclosed |
| US-7175850-B2 | Formulation for topical non-invasive application in vivo | IDEA AG (DE) | 2007-02-13 | — | — | US | disclosed |
| EP-1140021-B1 | IMPROVED FORMULATION FOR TOPICAL NON-INVASIVE APPLICATION IN VIVO | IDEA AG (DE) | 2004-08-04 | — | — | EP | disclosed |
| US-20020064524-A1 | Formulation for topical non-invasive application in vivo | IDEA AG (DE) | 2002-05-30 | — | — | US | disclosed |
| US-5190747-A | Fatty ester of glucose | LION CORPORATION (JP) | 1993-03-02 | — | — | US | disclosed |
| US-5109127-A | Fatty acid ester of hexose or an alkyl glucoside; tastless, good foaming power | LION CORPORATION (JP) | 1992-04-28 | — | — | US | disclosed |
| EP-0427210-A2 | Nonionic surface active agent | LION CORPORATION (JP) | 1991-05-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020064524-A1 | Formulation for topical non-invasive application in vivo | CUTA, LPO, GPX4 | PYGB 3056/4885PYGL 3840/4885PYGM 2917/4885 |
| US-20070184114-A1 | Formulation for topical non-invasive application in vivo | GPX4, LPO, MMP8 | PYGB 3045/4885PYGL 3694/4885PYGM 2869/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.